Viatris, the global healthcare company formed from the merger of Mylan and Upjohn, has long been viewed by investors as a slow-growing generics manufacturer. But Oppenheimer, in a new coverage initiation on Wednesday, argues that this perception is outdated and that the stock is being undervalued as a result.
The bank's analysts say Viatris is not just a generics play. They point to a pipeline of new product launches, including Gwyn Lo and Meloxicam, as well as growth opportunities in China. More importantly, they highlight upcoming Phase 3 trial readouts for two experimental drugs, selatogrel and cenerimod, which are scheduled for the first half of 2027. These could potentially transform the company's earnings trajectory if successful.
For everyday investors, the key takeaway is that Wall Street sometimes pigeonholes companies into simple categories. When a stock is labeled a "generics maker," it can trade at a lower valuation than a company with a more diversified portfolio. Oppenheimer's view is that Viatris deserves a more nuanced assessment.
What is Viatris?
Viatris is a global pharmaceutical company that sells a wide range of prescription drugs, including generics, branded medicines, and over-the-counter products. It was created in 2020 through the combination of Mylan and Pfizer's Upjohn business. The company has a large portfolio of established brands and a significant presence in emerging markets.
Generics are copies of brand-name drugs that have lost patent protection. They are typically cheaper and have lower profit margins than innovative medicines. As a result, companies that focus heavily on generics often face pricing pressure and competition, which can weigh on their stock valuations.
However, Viatris has been working to shift its mix toward higher-growth areas. The company has been investing in new product launches and expanding in markets like China, where demand for healthcare is rising rapidly. These efforts are part of a broader strategy to diversify beyond traditional generics.
What Oppenheimer Sees
Oppenheimer's initiation suggests that the market is not giving Viatris enough credit for these initiatives. The bank specifically calls out the potential of Gwyn Lo and Meloxicam, two products that are either recently launched or about to be launched. While the brief does not provide details on what these drugs treat, they are likely to contribute to near-term revenue growth.
More significant are the Phase 3 trial readouts for selatogrel and cenerimod. Phase 3 is the final stage of clinical testing before a drug can be submitted for regulatory approval. Positive results could lead to new product approvals, opening up substantial revenue opportunities. The fact that these readouts are expected in the first half of 2027 gives investors a clear timeline to watch.
Oppenheimer's stance is that the stock is "mispriced" because it is being valued as if it were a declining generics business, ignoring these potential catalysts. This is a common theme in the pharmaceutical sector, where pipeline value is often overlooked until late-stage data emerges.
What It Means for Investors
For investors, the main implication is that Viatris could offer upside if the company executes on its plans. However, it's important to remember that clinical trials are risky. Drugs can fail in Phase 3, and regulatory approvals are not guaranteed. The timeline is also long—readouts are more than two years away.
In the meantime, the company's existing business, including its generics portfolio and China operations, will determine its near-term financial performance. China is a key growth market for many drugmakers, and Viatris has been expanding its presence there. The success of new launches like Gwyn Lo and Meloxicam will also be closely watched.
Oppenheimer's coverage is just one analyst's opinion, but it highlights a broader point: investors should look beyond simple labels when evaluating a stock. A company that appears to be in a slow-growth sector may have hidden catalysts that could change its trajectory.
For those interested in the broader market context, Oppenheimer has also made similar calls on other stocks, suggesting the firm is actively looking for mispriced opportunities. Meanwhile, pharma growth is a theme in some economies, and China risk is a factor for many global companies.
Risks to Consider
Investing in pharmaceutical stocks carries inherent risks. Regulatory changes, pricing pressures, and competition can all affect earnings. Viatris also carries a significant amount of debt from its merger, which could limit its financial flexibility.
The company's reliance on generics means it is exposed to price erosion, a common industry trend. While new products and pipeline drugs could offset this, there is no guarantee they will succeed. The Phase 3 readouts are particularly high-stakes; a failure could send the stock lower.
That said, Oppenheimer's initiation is a positive signal. It suggests that at least one major bank sees value in Viatris that the broader market has overlooked. Whether that view proves correct will depend on the company's execution over the next few years.
For now, investors should keep an eye on the company's quarterly earnings reports, any updates on its pipeline, and the progress of its China expansion. The first half of 2027 will be a critical period, but there are many milestones to watch before then.
